Life Sciences 2022 Year in Review
XTalks
DECEMBER 21, 2022
Bluebird is also now back on track in evaluating its candidate gene therapy for sickle cell disease (SCD) after the FDA lifted a clinical hold on studies of the drug this month. There is also generally a low cost of return for gene therapies, particularly those for rare diseases. million for a single infusion. Personalized Medicine.
52 
Let's personalize your content